Table 4 Patient characteristics of the test group and the validation group. The p-values were obtained from the Chi-square test
Test group | Validation group | p-value | |
|---|---|---|---|
n patients (%) | n patients (%) | ||
Age | |||
≤ 64 years | 97 (54) | 94 (53) | |
≥ 65 years | 81 (46) | 84 (47) | 0.89 |
Gender | |||
Female | 47 (26) | 45 (25) | |
Male | 131 (74) | 133 (75) | 0.92 |
ECOG Performance status | |||
1-2 | 67 (38) | 66 (37) | |
3-4 | 111 (62) | 112 (63) | 0.96 |
Number of involved vertebrae | |||
1-2 | 71 (40) | 77 (43) | |
≥ 3 | 107 (60) | 101 (57) | 0.73 |
Ambulatory status prior to RT | |||
Not Ambulatory | 84 (47) | 78 (44) | |
Ambulatory before RT | 94 (53) | 100 (56) | 0.73 |
Other bone metastases | |||
No | 67 (38) | 76 (43) | |
Yes | 111 (62) | 102 (57) | 0.58 |
Visceral metastases | |||
No | 61 (34) | 56 (31) | |
Yes | 117 (66) | 122 (69) | 0.81 |
Interval from cancer diagnosis to radiotherapy of MSCC | |||
≤ 15 months | 148 (83) | 150 (84) | |
> 15 months | 30 (17) | 28 (16) | 0.92 |
Time developing motor deficits | |||
1-7 days | 74 (42) | 73 (41) | |
> 7 days | 104 (58) | 105 (59) | 0.95 |
Radiation regimen | |||
Short-course radiotherapy | 71 (40) | 72 (40) | |
Longer-course radiotherapy | 107 (60) | 106 (60) | 0.97 |